Sicker Patients Could Make Easier Case For Cornerstone’s Lixivaptan
Executive Summary
FDA Cardiovascular and Renal Drugs Advisory Committee tells company that a sicker patient population and different treatment goal in clinical trials might have produced more robust results.
You may also be interested in...
Patient Exclusion Analysis Coming From FDA; Changes In Trial Recruitment Could Follow
Subjects with psychiatric conditions are often excluded from trials, an agency study finds, which “doesn’t seem a good thing” to Bob Temple.
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.
Track-And-Trace: With Deadline a Year Away, Some Lessons from Early Adopters
EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.